Treatment for microscopic colitis usually involves medication to reduce symptoms. Learn about medication types and other ...

Findings were announced from a phase 3 trial evaluating guselkumab subcutaneous induction therapy in patients with moderately to severely active ulcerative colitis.

Vedolizumab outperforms infliximab in ulcerative colitis patients who fail first-line treatment, achieving better ...

In a US study, researchers found that 35% of adults with IBD screened positive for spondyloarthritis, despite having no known SpA diagnosis.

The active ingredient in Entyvio is vedolizumab. Entyvio is a biologic drug that belongs to a group of drugs called integrin receptor antagonists. (A biologic drug is made from living organisms ...

In patients with ulcerative colitis, vedolizumab outperformed infliximab as a second-line therapy following failure of anti-TNF therapy.

The European Commission will review the CHMP recommendation to determine issuing an expanded Marketing Authorisation, and a decision is expected in due course. 2 J&J Data on file (RF-452642). European ...

Ustekinumab was associated with lower risks of all-cause mortality and major adverse cardiovascular events when compared with vedolizumab in older adults with inflammatory bowel disease. Ustekinumab ...

She was diagnosed with steroid-dependent refractory UC and was treated with vedolizumab. Fifteen months later, gastrointestinal symptoms returned. After bacterial and viral infections were ruled out, ...

One significant abstract evaluated the predictive value of vedolizumab (VDZ) drug clearance (CL), a critical pharmacokinetic (PK) property, on therapeutic response and outcomes. The study was a ...

Our research The gastrointestinal (GI) epidemiology group focus on research on GI organs and diseases. Most of that research is based on the ESPRESSO study, which you can read more about on a separate ...